Vera Therapeutics Inc (VERA)
41.94
-0.75
(-1.76%)
USD |
NASDAQ |
May 16, 16:00
42.95
+1.01
(+2.41%)
After-Hours: 20:00
Vera Therapeutics Cash from Financing (Quarterly): 276.54M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 276.54M |
| December 31, 2023 | 24.83M |
| September 30, 2023 | 0.297M |
| June 30, 2023 | 0.432M |
| March 31, 2023 | 107.98M |
| December 31, 2022 | 20.71M |
| September 30, 2022 | 0.908M |
| June 30, 2022 | 0.048M |
| March 31, 2022 | 80.27M |
| Date | Value |
|---|---|
| December 31, 2021 | 4.921M |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 48.99M |
| March 31, 2021 | -0.028M |
| December 31, 2020 | 79.80M |
| September 30, 2020 | -0.094M |
| June 30, 2020 | 0.616M |
| March 31, 2020 | 4.967M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.094M
Minimum
Sep 2020
276.54M
Maximum
Mar 2024
38.31M
Average
4.921M
Median
Dec 2021
Cash from Financing (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | -357.50M |
| Alpine Immune Sciences Inc | 19.35M |
| Fate Therapeutics Inc | 95.49M |
| Mersana Therapeutics Inc | 5.829M |
| Equillium Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -33.83M |
| Cash from Investing (Quarterly) | -219.29M |
| Free Cash Flow | -99.72M |
| Free Cash Flow Per Share (Quarterly) | -0.6637 |
| Free Cash Flow Yield | -5.17% |